He 2016.

Methods	Study design: Randomised clinical trial Study duration: March 2015 to December 2015 Duration of follow‐up: 2 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by pathology or imaging examination; AFP > 400 μg/L; liver function of Child‐Pugh Class A or B; the number of tumours ≤ 2 Exclusion criteria: With portal vein tumour thrombus and extrahepatic metastasis Age (mean): TACE + MWA: 52.6 years; TACE alone: 52.9 years Male (n/total): TACE + MWA: 25/32; TACE alone: 22/28 Tumour diameter (mean): .TACE + MWA: 8.2 cm; TACE alone: 7.9 cm Child‐Pugh Class (patients): Class A: TACE + MWA: 13; TACE alone: 11 Class B: TACE + MWA: 19; TACE alone: 17
Interventions	TACE + MWA group (n = 32): TACE: Chemotherapeutic drugs: epirubicin 30‐50 mg and oxaliplatin 200‐150 mg MWA: CT‐guided MWA. Output power of 55‐60 W. The ablation time of per application was 5‐10 minutes. TACE group (n = 28): Chemotherapeutic drugs: epirubicin 30‐50 mg and oxaliplatin 200‐150 mg
Outcomes	Serum level of AFP Tumour response: measured by contrast‐enhanced CT or MRI at 1 month after treatment Adverse events 1‐ and 2‐year survival rates
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.